Finoriq research workspace
AGENUS INC (AGEN) SEC Filings & Filing Highlights
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for. Review AGEN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- Company
- AGENUS INC (AGEN)
- Ticker
- AGEN
- Market Cap
- $209.9M
- Latest Price
- $5.04
- Industry
- Biotech & Pharma
AGENUS INC (AGEN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AGENUS INC (AGEN).
| Event | Form | Date |
|---|---|---|
| On June 29, 2026, Agenus Inc. entered into an Amendment to Notes, Extension of Warrants and Sal...On June 29, 2026, Agenus Inc. (the “Company”) entered into an Amendment to Notes, Extension of Warrants and Sale of New Warrants (the “Amen... | 8-K1.01 | 2026-07-06 |
| The Company’s stockholders approved the Class II Director nominees recommended for election in...Agenus Inc. (the “Company”) held its Annual Meeting of Stockholders on June 16, 2026 (the “Annual Meeting”). A total of 27,098,077 shares o... | 8-K5.07 | 2026-06-23 |
| Departure of Principal Accounting Officer On May 12, 2026, Austin Charette, Senior Director, Fi...Departure of Principal Accounting Officer On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Princip... | 8-K5.02 | 2026-05-15 |
| Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Glo...Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | 8-K2.02 | 2026-05-11 |
| /s/ Garo H. ArmenOn March 24, 2026, the United States District Court for the District of Massachusetts issued a Memorandum and Order in Byron Olsen, Individ... | 8-K8.01 | 2026-03-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.